May 18, 2026 08:34AM
May 7, 2026 01:00AM
Apr 19, 2026 10:00AM
Dec 22, 2025 07:06AM
Oct 24, 2025 08:29AM
Aug 26, 2025 05:26AM
Aug 25, 2025 04:30PM Oppenheimer Reiterates Outperform Rating on argenx SE (ARGX)
Aug 25, 2025 02:15AM
Jul 6, 2025 10:00AM
Jun 30, 2025 04:13PM
Jun 30, 2025 11:40AM
Apr 11, 2025 09:44AM
Apr 11, 2025 07:08AM
Apr 11, 2025 06:36AM H.C. Wainwright Reiterates Buy Rating on argenx SE (ARGX)
Apr 11, 2025 06:29AM
Apr 10, 2025 06:02PM
Apr 10, 2025 05:47PM
Jan 4, 2025 04:00PM
Jan 2, 2025 12:51PM
Nov 22, 2024 11:07AM
Oct 15, 2024 01:00AM argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Fo
Sep 19, 2024 01:00AM
Jul 29, 2024 06:55AM
Jul 26, 2024 06:47AM
Jul 16, 2024 12:15AM
Jun 24, 2024 06:58AM
Jun 24, 2024 06:35AM
Jun 21, 2024 04:52PM argenx (ARGX) Announces FDA Approval of VYVGART Hytrulo
Jun 21, 2024 04:50PM
Apr 16, 2024 01:00AM
Mar 27, 2024 02:00AM
Feb 20, 2024 03:10AM
Feb 20, 2024 01:00AM
Jan 8, 2024 05:32AM
Jan 8, 2024 01:00AM argenx Highlights 2024 Strategic Priorities
Jun 30, 2023 09:39AM
Jun 20, 2023 06:13PM
Jun 20, 2023 06:12PM
Apr 18, 2023 01:00AM
Mar 2, 2023 01:00AM
Jan 27, 2023 01:00AM
Dec 10, 2022 11:30AM argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
Nov 30, 2022 06:20AM
Nov 30, 2022 01:00AM
Nov 22, 2022 01:00AM
Oct 27, 2022 01:00AM
Sep 21, 2022 01:00AM
Sep 21, 2022 01:00AM
Jul 28, 2022 01:00AM argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
May 5, 2022 05:45AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All